Skip to main content

Table 2 Adjusted hazard ratios (95%CI) for overall survival and breast cancer-specific survival by tumor CYP27A1 expression in MDCS cohort

From: CYP27A1 expression is associated with risk of late lethal estrogen receptor-positive breast cancer in postmenopausal patients

  Model 0a Model 1b Model 2c
Cases Events CYP27A1 high vs low HR (95%CI) Cases Events CYP27A1 high vs low HR (95%CI) Cases Events CYP27A1 high vs low HR (95%CI)
Follow-up period ≤ 5 years
Overall survival
  All 645 76 0.97 (0.56–1.69) 569 69 0.86 (0.47–1.57) 514 63 0.68 (0.35–1.31)
   P = 0.92    P = 0.63    P = 0.25
  ER+ 522 52 1.05 (0.53–1.03) 498 51 1.09 (0.54–2.19) 448 47 0.91 (0.43–1.93)
   P = 0.87    P = 0.81    P = 0.81
  ER+ and age ≥ 55 yrs 472 51 1.10 (0.55–2.21) 450 50 1.11 (0.55–2.23) 400 46 0.97 (0.46–2.05)
   P = 0.78    P = 0.76    P = 0.93
Breast cancer-specific survival
  All 645 46 0.92 (0.44–1.93) 569 41 0.67 (0.30–1.51) 514 38 0.54 (0.22–1.31)
   P = 0.83    P = 0.34    P = 0.17
  ER+ 522 26 0.61 (0.18–2.03) 498 26 0.63 (0.19–2.10) 448 25 0.57 (0.16–1.95)
   P = 0.42    P = 0.45    P = 0.37
  ER+ and age ≥ 55 yrs 472 25 0.64 (0.19–2.16) 450 25 0.64 (0.19–2.14) 400 24 0.63 (0.18–2.15)
   P = 0.47    P = 0.47    P = 0.46
Follow-up period > 5 years
Overall survival
  All 567 145 1.66 (1.14–2.43) 498 129 1.89 (1.25–2.85) 449 123 1.93 (1.26–2.97)
   P = 0.009    P = 0.003    P = 0.003
  ER+ 468 122 1.76 (1.14–2.71) 445 117 1.79 (1.16–2.77) 399 112 1.78 (1.13–2.80)
   P = 0.01    P = 0.009    P = 0.01
  ER+ and age ≥ 55 yrs 419 112 1.85 (1.18–2.91) 398 107 1.91 (1.22–3.03) 352 102 1.99 (1.24–3.21)
   P = 0.007    P = 0.005    P = 0.004
Breast cancer-specific survival
  All 567 66 2.18 (1.28–3.73) 498 60 2.25 (1.26–4.01) 449 58 2.33 (1.28–4.23)
   P = 0.004    P = 0.006    P = 0.006
  ER+ 468 54 2.22 (1.19–4.12) 445 54 2.18 (1.18–4.03) 399 52 2.26 (1.20–4.27)
   P = 0.01    P = 0.01    P = 0.01
  ER+ and age ≥ 55 yrs 419 46 2.56 (1.33–4.91) 398 46 2.57 (1.34–4.94) 352 44 2.78 (1.41–5.51)
   P = 0.005    P = 0.005    P = 0.003
  1. HR hazard ratio, CI confidence interval, ER+ estrogen receptor positive
  2. aModel 0: adjusted for FFPE block storage duration
  3. bModel 1: adjusted for age at diagnosis, tumor size, lymph node involvement, ER expression, tumor histological grade and FFPE block storage duration
  4. cModel 2: Model 1 + adjusted for local (radiotherapy) and systemic (endocrine and chemotherapy) treatments